After more than two-and-a-half years of development work and onsite testing, John Kelly, CEO of Sydney, Australia-based Atomo Diagnostics, believes that his company has developed the test platform, AtomoRapid, to address critical errors common in test kit solutions.

READ: Self-Testing Takes Center Stage

The new test’s purpose is to decrease false positives while making the test easier to use. Previous common failure points include the blood transfer point (pipette), the lancet, and the complexity of the test – all things addressed with a new profile that is essentially half the size of an iPhone.